Company news

Sensei Biotherapeutics, Inc. news in 2025

Sensei Biotherapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Sensei Biotherapeutics Reports Third Quarter 2025 Financial Results

November 14, 2025

Sensei Biotherapeutics Announces Initiation of Strategic Review to Maximize Shareholder Value

October 30, 2025

Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

October 20, 2025

Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable Progression Free Survival Data for Solnerstotug in PD-(L)1 Resistant Tumors at the ESMO Congress 2025

October 17, 2025

Sensei Biotherapeutics to Host Virtual KOL Event to Discuss Full Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors on October 20, 2025

September 23, 2025

Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

August 5, 2025

Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025

July 30, 2025

Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split

June 13, 2025

Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress

May 6, 2025

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

April 2, 2025

Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress

March 28, 2025

Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors

March 27, 2025

Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference

February 3, 2025

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

January 7, 2025

Decks in 2025